CN102859355B - 通过检测kras突变和rtk表达水平来测定细胞对b-raf抑制剂治疗的敏感性 - Google Patents

通过检测kras突变和rtk表达水平来测定细胞对b-raf抑制剂治疗的敏感性 Download PDF

Info

Publication number
CN102859355B
CN102859355B CN201080048007.0A CN201080048007A CN102859355B CN 102859355 B CN102859355 B CN 102859355B CN 201080048007 A CN201080048007 A CN 201080048007A CN 102859355 B CN102859355 B CN 102859355B
Authority
CN
China
Prior art keywords
ras
raf
mutant
inhibitor
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080048007.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102859355A (zh
Inventor
G.哈齐瓦西利奥
S.马利克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN102859355A publication Critical patent/CN102859355A/zh
Application granted granted Critical
Publication of CN102859355B publication Critical patent/CN102859355B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201080048007.0A 2009-08-24 2010-08-24 通过检测kras突变和rtk表达水平来测定细胞对b-raf抑制剂治疗的敏感性 Expired - Fee Related CN102859355B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23646609P 2009-08-24 2009-08-24
US61/236,466 2009-08-24
US30114910P 2010-02-03 2010-02-03
US61/301,149 2010-02-03
PCT/US2010/046520 WO2011028540A1 (en) 2009-08-24 2010-08-24 Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels

Publications (2)

Publication Number Publication Date
CN102859355A CN102859355A (zh) 2013-01-02
CN102859355B true CN102859355B (zh) 2015-10-07

Family

ID=43649583

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080048007.0A Expired - Fee Related CN102859355B (zh) 2009-08-24 2010-08-24 通过检测kras突变和rtk表达水平来测定细胞对b-raf抑制剂治疗的敏感性

Country Status (15)

Country Link
US (2) US20120214828A1 (https=)
EP (1) EP2470898A4 (https=)
JP (1) JP2013502236A (https=)
KR (1) KR20120050493A (https=)
CN (1) CN102859355B (https=)
AU (1) AU2010289794B2 (https=)
BR (1) BR112012003926A2 (https=)
CA (1) CA2771369A1 (https=)
IL (2) IL218099A0 (https=)
IN (1) IN2012DN01403A (https=)
MX (1) MX338856B (https=)
MY (1) MY165154A (https=)
RU (2) RU2553379C2 (https=)
SG (2) SG178866A1 (https=)
WO (1) WO2011028540A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008337286B2 (en) 2007-12-19 2014-08-07 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
NZ601085A (en) 2010-02-01 2015-04-24 Cancer Rec Tech Ltd 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
AU2012312515A1 (en) * 2011-09-19 2014-03-13 Genentech, Inc. Combination treatments comprising c-met antagonists and B-raf antagonists
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
US20150017261A1 (en) * 2012-01-11 2015-01-15 Duke University Methods of Treating and Preventing Cancer by Disrupting the Binding of Copper in the Map Kinase Pathway
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
TR201904980T4 (tr) 2012-08-07 2019-05-21 Novartis Ag Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar.
DK2884979T3 (da) 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
US20150273057A1 (en) * 2012-10-25 2015-10-01 Glaxosmithkline Llc Combination
EP2786764B1 (en) 2013-04-01 2017-03-08 Samsung Electronics Co., Ltd. Combination therapy using anti-c-met antibody and sorafenib
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
EP3805404A1 (en) 2014-05-13 2021-04-14 Board of Regents, The University of Texas System Gene mutations and copy number alterations of egfr, kras and met
ES2827024T3 (es) * 2014-12-23 2021-05-19 Dot Therapeutics 1 Inc Combinación de inhibidores de Raf y de taxanos
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
EP3450555B1 (en) * 2016-04-28 2020-11-18 Denka Company Limited Method for determining tolerance of cancer cell to epidermal growth factor receptor inhibitor
JP7341060B2 (ja) 2017-02-10 2023-09-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
EP3732285A1 (en) 2017-12-28 2020-11-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
BR112020025764A2 (pt) 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
IL297650A (en) * 2020-04-27 2022-12-01 Verastem Inc Methods of treating abnormal cell growth
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101355928A (zh) * 2005-04-26 2009-01-28 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
US20090075267A1 (en) * 2007-03-13 2009-03-19 Salvatore Siena K-ras and B-raf mutations and anti-EGFr antibody therapy
US20090202989A1 (en) * 2005-06-28 2009-08-13 Hillan Kenneth J Egfr and kras mutations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1766068A4 (en) * 2004-06-04 2010-03-03 Genentech Inc EGFR Mutations
ATE520979T1 (de) * 2005-08-24 2011-09-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101355928A (zh) * 2005-04-26 2009-01-28 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
US20090202989A1 (en) * 2005-06-28 2009-08-13 Hillan Kenneth J Egfr and kras mutations
US20090075267A1 (en) * 2007-03-13 2009-03-19 Salvatore Siena K-ras and B-raf mutations and anti-EGFr antibody therapy

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
antitumor efficacy of the novel raf inhibitor gdc-0879 is predicted by brafv600e mutational status and sustained extracellular signal-regulated kinaes/mitogen-activated protein kinase pathway suppression;hoeflich等;《cancer research》;20090401;第69卷(第7期);第3042-3051页 *
bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the raf/mek/erk pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis;wilhelm等;《cancer resesrch》;20041001;第64卷;第7099-7109页 *
gene expression deregulation by kras g12d and G12V in a braf v600e context;monticone等;《molecular cancer》;20081216;第7卷(第1期);第92页 *
inherent resistance to epidermal growth factor receptor antibodies in refractory metastatic colorectal cancer;gala等;《journal of medical science》;20050515;第9卷(第4期);第165-174页 *
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression;Olivera等;《ONCOGENOMICS》;20060904;第26卷;摘要，第160页，附图1-2 *
k-ras oncogene mutations in sporadic colorectal cancer in the netherlands cohort study;brink等;《carcinogenesis》;20031231;第24卷(第4期);第703-710页 *
sorafenib inhibits non-small cell lung cancer cell growth by targeting b-raf in kras wild-type cells and c-raf;takezawa等;《cancer res.》;20090815;第69卷(第16期);第6515-6521页 *

Also Published As

Publication number Publication date
US20150164895A1 (en) 2015-06-18
EP2470898A1 (en) 2012-07-04
RU2012111231A (ru) 2013-10-10
MY165154A (en) 2018-02-28
RU2553379C2 (ru) 2015-06-10
SG10201402917XA (en) 2014-08-28
KR20120050493A (ko) 2012-05-18
WO2011028540A1 (en) 2011-03-10
US20120214828A1 (en) 2012-08-23
CN102859355A (zh) 2013-01-02
AU2010289794B2 (en) 2014-10-02
HK1175248A1 (zh) 2013-06-28
RU2015104058A (ru) 2015-06-10
IL235398A0 (en) 2014-12-31
MX338856B (es) 2016-05-03
IN2012DN01403A (https=) 2015-06-05
BR112012003926A2 (pt) 2020-08-11
MX2012002292A (es) 2012-03-19
AU2010289794A1 (en) 2012-04-05
IL218099A0 (en) 2012-04-30
CA2771369A1 (en) 2011-03-10
JP2013502236A (ja) 2013-01-24
SG178866A1 (en) 2012-04-27
EP2470898A4 (en) 2013-03-13

Similar Documents

Publication Publication Date Title
CN102859355B (zh) 通过检测kras突变和rtk表达水平来测定细胞对b-raf抑制剂治疗的敏感性
Duffaud et al. Gastrointestinal stromal tumors: biology and treatment
EP2820151B1 (en) Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status
US20220170107A1 (en) Phosphatidylinositol-3-kinase pathway biomarkers
Zhang et al. Biomarker development in MET-targeted therapy
Ariyasu et al. High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer
US20130230511A1 (en) Biomarkers for response to tyrosine kinase pathway inhibitors in cancer
de Melo Gagliato et al. Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit
CN103717616B (zh) 表皮生长因子受体基因中的突变
US20060204966A1 (en) Treatment of cancers expressing p95 erbb2
de Castro et al. β-catenin expression pattern in primary oesophageal squamous cell carcinoma. Relationship with clinicopathologic features and clinical outcome
HK1175248B (en) Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
Ozretić et al. The role of molecular diagnostics in cancer diagnosis and treatment
AU2014203196A1 (en) Determining sensitivity of cells to B-Raf inhibitor treatment by detecting Kras mutation and RTK expression levels
US20110269139A1 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
Goetsch et al. Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers
Pender et al. Understanding lung cancer molecular subtypes
Lo et al. Molecular Pathology of Lung Tumors
Catenacci et al. 561 Development of a Quantitative Gastroesophageal Cancer Selected Reaction Monitoring Mass Spectrometric Multiplex Assay for Use in FFPE Tumor Tissues
Semadhi et al. Lung cancer: Biomarkers, tyrosine kinase inhibitors and monoclonal antibodies
JP2025528800A (ja) Ｅｇｆｒキナーゼ活性の阻害剤に対する応答を予測するための方法
WO2022229846A1 (en) Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor
HK1199744B (en) Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1175248

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1175248

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151007